Dr. Alan Parr has worked in Pharmaceutical Sciences for over 33 years, with most time being spent in the big pharma sector, specifically Glaxo, GlaxoWellcome and GlaxoSmithKline. Dr. Parr’s roles in big pharma include being a formulation scientist, formulation manager and Director of Biopharmaceutics, and responsibilities have ranged from the development of formulations from the early development phase all the way through to the scale-up of commercial size batches for the marketplace. Specific activities include physical property characterization, formulation screening, formulation development, manufacturing clinical supplies, transferring a product to production and managing projects. He was intimately involved with the creation, review and submission of regulatory documents to the US Food and Drug Administration, including Investigational New Drug (IND) applications, New Drug Applications (NDA), as well as foreign filings (Marketing Authorization Applications (MAA)). Since June 2015, Dr. Parr has served as a consultant to numerous small pharmaceutical companies and as a principal investor for 2 NIH grants where his primary responsibility was to file an IND for an NCE that was being developed. Dr. Parr earned his Pharm.D. degree from the University of Nebraska College of Pharmacy and his Ph.D. from the University of Kentucky College of Pharmacy.
